tiprankstipranks
Trending News
More News >
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
Advertisement

Rhythm Pharmaceuticals (RYTM) Stock Statistics & Valuation Metrics

Compare
528 Followers

Total Valuation

Rhythm Pharmaceuticals has a market cap or net worth of $5.73B. The enterprise value is $5.58B.
Market Cap$5.73B
Enterprise Value$5.58B

Share Statistics

Rhythm Pharmaceuticals has 65,680,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding65,680,300
Owned by Insiders0.68%
Owned by Institutions0.59%

Financial Efficiency

Rhythm Pharmaceuticals’s return on equity (ROE) is -11.99 and return on invested capital (ROIC) is -96.06%.
Return on Equity (ROE)-11.99
Return on Assets (ROA)-0.66
Return on Invested Capital (ROIC)-96.06%
Return on Capital Employed (ROCE)-0.96
Revenue Per Employee459.81K
Profits Per Employee-920.86K
Employee Count283
Asset Turnover0.33
Inventory Turnover0.71

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio
PS Ratio0.00
PB Ratio34.36
Price to Fair Value157.14
Price to FCF-76.93
Price to Operating Cash Flow-49.38
PEG Ratio-0.92

Income Statement

In the last 12 months, Rhythm Pharmaceuticals had revenue of 130.13M and earned -260.60M in profits. Earnings per share was -4.21.
Revenue130.13M
Gross Profit116.76M
Operating Income-265.50M
Pretax Income-260.26M
Net Income-260.60M
EBITDA-238.09M
Earnings Per Share (EPS)-4.21

Cash Flow

In the last 12 months, operating cash flow was -113.49M and capital expenditures 40.00M, giving a free cash flow of -73.49M billion.
Operating Cash Flow-113.49M
Free Cash Flow-73.49M
Free Cash Flow per Share-1.12

Dividends & Yields

Rhythm Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.88
52-Week Price Change77.37%
50-Day Moving Average69.79
200-Day Moving Average59.71
Relative Strength Index (RSI)66.82
Average Volume (3m)839.50K

Important Dates

Rhythm Pharmaceuticals upcoming earnings date is Aug 5, 2025, TBA (Confirmed).
Last Earnings DateMay 7, 2025
Next Earnings DateAug 5, 2025
Ex-Dividend Date

Financial Position

Rhythm Pharmaceuticals as a current ratio of 3.24, with Debt / Equity ratio of 2.49%
Current Ratio3.24
Quick Ratio3.08
Debt to Market Cap<0.01
Net Debt to EBITDA0.36
Interest Coverage Ratio-12.89

Taxes

In the past 12 months, Rhythm Pharmaceuticals has paid 346.00K in taxes.
Income Tax346.00K
Effective Tax Rate>-0.01

Enterprise Valuation

Rhythm Pharmaceuticals EV to EBITDA ratio is -13.98, with an EV/FCF ratio of -29.24.
EV to Sales25.59
EV to EBITDA-13.98
EV to Free Cash Flow-29.24
EV to Operating Cash Flow-29.24

Balance Sheet

Rhythm Pharmaceuticals has $314.49M in cash and marketable securities with $4.06M in debt, giving a net cash position of -$310.43M billion.
Cash & Marketable Securities$314.49M
Total Debt$4.06M
Net Cash-$310.43M
Net Cash Per Share-$4.73
Tangible Book Value Per Share$2.60

Margins

Gross margin is 89.49%, with operating margin of -204.04%, and net profit margin of -200.27%.
Gross Margin89.49%
Operating Margin-204.04%
Pretax Margin-200.00%
Net Profit Margin-200.27%
EBITDA Margin-182.97%
EBIT Margin-184.17%

Analyst Forecast

The average price target for Rhythm Pharmaceuticals is $104.21, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$104.21
Price Target Upside20.54% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast48.88%
EPS Growth Forecast39.30%

Scores

Smart Score7
AI Score61.7
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis